Trevi Therapeutics Q1 2025: Unraveling Contradictions in Clinical Trial Timelines and Study Impacts
Generado por agente de IAAinvest Earnings Call Digest
lunes, 19 de mayo de 2025, 9:19 am ET1 min de lectura
TRVI--
Powered discontinuation rate for the CORAL trial, timeline for respiratory physiology study, respiratory physiology study timeline, and HAP study status and impact are the key contradictions discussed in TreviTRVI-- Therapeutics' latest 2025Q1 earnings call.
Positive Clinical Trial Results:
- Trevi TherapeuticsTRVI-- reported significant results from the Phase 2a RIVER trial in refractory chronic cough (RCC) patients, with Haduvio meeting the primary endpoint with a statistically significant reduction in 24-hour objective cough frequency, achieving a P value of less than 0.0001.
- The positive outcomes are due to Haduvio's central and peripheral mechanism, which addresses cough hypersensitivity at the brain level and shows a broader effect across different cough counts compared to other peripheral-only therapies.
Completing Enrollment for Phase 2b CORAL Trial:
- Trevi Therapeutics completed enrollment in the Phase 2b CORAL trial for the treatment of chronic cough in IPF patients, with approximately 160 patients enrolled in 10 countries and across 60 sites.
- The completion of enrollment is part of the company's strategy to advance its development program for both chronic cough conditions of IPF and RCC.
FDA Guidance and Collaboration:
- Trevi received clear guidance from the FDA through a Type C request, with the FDA meeting their goal date and providing responses on a technical matter in the development program.
- The timely and effective communication from the FDA is crucial for Trevi to continue its development programs, and the new leadership is expected to prioritize this aspect of the FDA's role.
Strategic Partnership and Commercialization:
- Trevi Therapeutics is engaged in strategic conversations with potential partners for commercialization in Europe and Japan, while preparing to handle US operations independently.
- This strategy is based on the company's data-driven approach and its readiness to handle commercialization without a straight acquisition.
Positive Clinical Trial Results:
- Trevi TherapeuticsTRVI-- reported significant results from the Phase 2a RIVER trial in refractory chronic cough (RCC) patients, with Haduvio meeting the primary endpoint with a statistically significant reduction in 24-hour objective cough frequency, achieving a P value of less than 0.0001.
- The positive outcomes are due to Haduvio's central and peripheral mechanism, which addresses cough hypersensitivity at the brain level and shows a broader effect across different cough counts compared to other peripheral-only therapies.
Completing Enrollment for Phase 2b CORAL Trial:
- Trevi Therapeutics completed enrollment in the Phase 2b CORAL trial for the treatment of chronic cough in IPF patients, with approximately 160 patients enrolled in 10 countries and across 60 sites.
- The completion of enrollment is part of the company's strategy to advance its development program for both chronic cough conditions of IPF and RCC.
FDA Guidance and Collaboration:
- Trevi received clear guidance from the FDA through a Type C request, with the FDA meeting their goal date and providing responses on a technical matter in the development program.
- The timely and effective communication from the FDA is crucial for Trevi to continue its development programs, and the new leadership is expected to prioritize this aspect of the FDA's role.
Strategic Partnership and Commercialization:
- Trevi Therapeutics is engaged in strategic conversations with potential partners for commercialization in Europe and Japan, while preparing to handle US operations independently.
- This strategy is based on the company's data-driven approach and its readiness to handle commercialization without a straight acquisition.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
SOBRE NOSOTROS
Nuestra historiaAutores de noticiasBase de conocimientosPolítica de privacidadTérmino de usoDescargo de responsabilidad de corretaje de tercerosTérminos de uso de AIMEDivulgaciones de riesgos de AInvest AICarrerasCONTÁCTENOS
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comentarios
Aún no hay comentarios